Your browser doesn't support javascript.
loading
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.
Ostkamp, Patrick; Salmen, Anke; Pignolet, Béatrice; Görlich, Dennis; Andlauer, Till F M; Schulte-Mecklenbeck, Andreas; Gonzalez-Escamilla, Gabriel; Bucciarelli, Florence; Gennero, Isabelle; Breuer, Johanna; Antony, Gisela; Schneider-Hohendorf, Tilman; Mykicki, Nadine; Bayas, Antonios; Then Bergh, Florian; Bittner, Stefan; Hartung, Hans-Peter; Friese, Manuel A; Linker, Ralf A; Luessi, Felix; Lehmann-Horn, Klaus; Mühlau, Mark; Paul, Friedemann; Stangel, Martin; Tackenberg, Björn; Tumani, Hayrettin; Warnke, Clemens; Weber, Frank; Wildemann, Brigitte; Zettl, Uwe K; Ziemann, Ulf; Müller-Myhsok, Bertram; Kümpfel, Tania; Klotz, Luisa; Meuth, Sven G; Zipp, Frauke; Hemmer, Bernhard; Hohlfeld, Reinhard; Brassat, David; Gold, Ralf; Gross, Catharina C; Lukas, Carsten; Groppa, Sergiu; Loser, Karin; Wiendl, Heinz; Schwab, Nicholas.
Afiliação
  • Ostkamp P; Department of Neurology with Institute of Translational Neurology, University of Muenster, 48149 Muenster, Germany.
  • Salmen A; Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany.
  • Pignolet B; Neurology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.
  • Görlich D; Neurosciences Department, Centres de Ressources et de Compétences-Sclérose en Plaques, Centre Hospitalier Univeresitaire Toulouse, 31300 Toulouse, France.
  • Andlauer TFM; Center for Physiopathology of Toulouse Purpan, INSERM U1043-CNRS U5282, Université Toulouse III, 31330 Toulouse, France.
  • Schulte-Mecklenbeck A; Institute of Biostatistics and Clinical Research, University of Muenster, 48149 Muenster, Germany.
  • Gonzalez-Escamilla G; Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Bucciarelli F; Department of Neurology, School of Medicine, Technical University of Munich, 80333 Munich, Germany.
  • Gennero I; Department of Neurology with Institute of Translational Neurology, University of Muenster, 48149 Muenster, Germany.
  • Breuer J; Department of Neurology, Focus Program Translational Neuroscience, Rhine Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
  • Antony G; Neurosciences Department, Centres de Ressources et de Compétences-Sclérose en Plaques, Centre Hospitalier Univeresitaire Toulouse, 31300 Toulouse, France.
  • Schneider-Hohendorf T; Center for Physiopathology of Toulouse Purpan, INSERM U1043-CNRS U5282, Université Toulouse III, 31330 Toulouse, France.
  • Mykicki N; Center for Physiopathology of Toulouse Purpan, INSERM U1043-CNRS U5282, Université Toulouse III, 31330 Toulouse, France.
  • Bayas A; Institut Federatif de Biologie, Centre Hospitalier Univeresitaire Toulouse, Purpan University Hospital, 31300 Toulouse, France.
  • Then Bergh F; Department of Neurology with Institute of Translational Neurology, University of Muenster, 48149 Muenster, Germany.
  • Bittner S; Central Information Office German Competence Network of Multiple Sclerosis, Philipps-University Marburg, 35037 Marburg, Germany.
  • Hartung HP; Department of Neurology with Institute of Translational Neurology, University of Muenster, 48149 Muenster, Germany.
  • Friese MA; Department of Dermatology, University of Muenster, 48149 Muenster, Germany.
  • Linker RA; Department of Neurology, University Hospital Augsburg, 86156 Augsburg, Germany.
  • Luessi F; Department of Neurology, University of Leipzig, 04109 Leipzig, Germany.
  • Lehmann-Horn K; Department of Neurology, Focus Program Translational Neuroscience, Rhine Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
  • Mühlau M; Department of Neurology, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.
  • Paul F; Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Stangel M; Department of Neurology, University of Regensburg, 93053 Regensburg, Germany.
  • Tackenberg B; Department of Neurology, Focus Program Translational Neuroscience, Rhine Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
  • Tumani H; Department of Neurology, School of Medicine, Technical University of Munich, 80333 Munich, Germany.
  • Warnke C; Munich Cluster for Systems Neurology, 81377 Munich, Germany.
  • Weber F; Munich Cluster for Systems Neurology, 81377 Munich, Germany.
  • Wildemann B; Technische Universität München-Neuroimaging Center, Klinikum Rechts der Isar, Technische Universität München, 80333 Munich, Germany.
  • Zettl UK; NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Ziemann U; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, 13125 Berlin, Germany.
  • Müller-Myhsok B; Department of Neurology, Charité-Universitätsmedizin Berlin, 13125 Berlin, Germany.
  • Kümpfel T; Berlin Institute of Health, 10178 Berlin, Germany.
  • Klotz L; Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.
  • Meuth SG; Clinical Neuroimmunology Group, Department of Neurology, Philipps-University of Marburg, 35037 Marburg, Germany.
  • Zipp F; Department of Neurology, University of Ulm, 89081 Ulm, Germany.
  • Hemmer B; Clinic of Neurology Dietenbronn, 88477 Schwendi, Germany.
  • Hohlfeld R; Department of Neurology, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.
  • Brassat D; Department of Neurology, University Hospital Cologne, 50924 Cologne, Germany.
  • Gold R; Neurological Clinic Cham, Sana Kliniken des Landkreises Cham GmbH, 93413 Cham, Germany.
  • Gross CC; Department of Neurology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Lukas C; Department of Neurology, Neuroimmunological Section, University of Rostock, 18051 Rostock, Germany.
  • Groppa S; Department of Neurology & Stroke, Eberhard-Karls-Universität Tübingen, 72074 Tübingen, Germany.
  • Loser K; Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Wiendl H; Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, United Kingdom.
  • Schwab N; Munich Cluster for Systems Neurology, 81377 Munich, Germany.
Proc Natl Acad Sci U S A ; 118(1)2021 01 05.
Article em En | MEDLINE | ID: mdl-33376202
ABSTRACT
Multiple sclerosis (MS) disease risk is associated with reduced sun-exposure. This study assessed the relationship between measures of sun exposure (vitamin D [vitD], latitude) and MS severity in the setting of two multicenter cohort studies (nNationMS = 946, nBIONAT = 990). Additionally, effect-modification by medication and photosensitivity-associated MC1R variants was assessed. High serum vitD was associated with a reduced MS severity score (MSSS), reduced risk for relapses, and lower disability accumulation over time. Low latitude was associated with higher vitD, lower MSSS, fewer gadolinium-enhancing lesions, and lower disability accumulation. The association of latitude with disability was lacking in IFN-ß-treated patients. In carriers of MC1Rrs1805008(T), who reported increased sensitivity toward sunlight, lower latitude was associated with higher MRI activity, whereas for noncarriers there was less MRI activity at lower latitudes. In a further exploratory approach, the effect of ultraviolet (UV)-phototherapy on the transcriptome of immune cells of MS patients was assessed using samples from an earlier study. Phototherapy induced a vitD and type I IFN signature that was most apparent in monocytes but that could also be detected in B and T cells. In summary, our study suggests beneficial effects of sun exposure on established MS, as demonstrated by a correlative network between the three factors Latitude, vitD, and disease severity. However, sun exposure might be detrimental for photosensitive patients. Furthermore, a direct induction of type I IFNs through sun exposure could be another mechanism of UV-mediated immune-modulation in MS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitamina D / Monócitos / Receptor Tipo 1 de Melanocortina / Transcriptoma / Esclerose Múltipla Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitamina D / Monócitos / Receptor Tipo 1 de Melanocortina / Transcriptoma / Esclerose Múltipla Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha